Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive randomized trial of Serelaxin (RLX030) in women with pre-eclampsia
2011-001617-14Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2012
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in preeclampsia comparing Serelaxin with Placebo (2 arms). Primary endpoint: Safety and tolerability (Part 1). Started Jul 2012; status: terminated.
02
Drugs
serelaxin
03
Conditions
preeclampsia
Beyond the preview
Go deeper on 2011-001617-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001617-14.